A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    Dec 30, 2024
  • participants needed
    75
  • sponsor
    Wuhan YZY Biopharma Co., Ltd.
Updated on 27 August 2021

Summary

The main purpose of this Phase I study is to access the safety and tolerability of Y150 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.

Description

This is a Phase I, open-labeldose-escalation trial in patients with relapsed or refractory multiple myeloma. There are two parts of the study: a dose-escalation part and a dose-expansion part. Dose escalation follows an accelerated design initially with 2 single subject cohorts (Cohorts 1-2) and switches to a classical 3+3 design (Cohorts 3-7). Dose-expansion means that at least 9 subjects (included subjects of the dose-escalation part) will be selected in 1 - 3 dose levels to focus on the pharmacokinetics (PK) / pharmacodynamic (PD) features and recommended dose for Phase II (RP2D). Additional purpose of the study is to find out whether the study drug has anti-tumor effects.

Details
Condition Relapsed or Refractory Multiple Myeloma
Treatment Y150
Clinical Study IdentifierNCT05011097
SponsorWuhan YZY Biopharma Co., Ltd.
Last Modified on27 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female 18 years
Subject has a history of multiple myeloma with relapsed and refractory disease, and must have received at least 2 prior multiple myeloma treatment regimens (including a proteasome inhibitor and an immunomodulatory agent), or can not tolerate the toxicity of PIs and IMIDS; or have drug resistance to one and toxic intolerance to the other
Relapsed multiple myeloma is defined as IMWG criteria in 2016, including clinical relapse or relapse after CR
Refractory multiple myeloma is defined as failure of initial or salvage therapy to achieve at least a minimal response (only achieve SD after treatment 2 cycles ), or disease progression during treatment or within 60 days after the last treatment
Subjects must have measurable disease, including at least one of the criteria below
M-protein 10 g/L by SPEP/immunofixation for subjects with immunoglobulin class G (IgG) myeloma , M-protein 5g/L for subjects with IgA, IgD, IgE, IgM myeloma or
200 mg/24 hours urine collection by UPEP or
Serum free light chain (FLC) levels 100 mg/L and an abnormal kappa/lambda (/) ratio in patients without detectable serum or urine M-protein
The interval between the last anti-tumor treatment and the first administration of Y150 (including PIS and IMADs) 4 weeks, the interval between CD38 mAb administration and the first administration of Y150 12 weeks
ECOG performance status 0 - 2
Life expectancy 3 months
Adequate hematological function as evidenced by meeting all the following
requirements
Absolute neutrophil count 1.0109/L (growth factor support not allowed within 48h)
Hemoglobin > 70 g/L( without blood transfusion within 7 days)
Platelet count 50109/L(without transfusion within 7 days)
Adequate hepatic function as evidenced by meeting all the following requirements
Total bilirubin 1.5 upper limit of normal (ULN)
Aspartate aminotransferase (AST), and alanine aminotransferase (ALT) 2.5 ULN
Calculated creatinine clearance (CrCL) 30 mL/min
Understand and voluntarily sign written informed consent

Exclusion Criteria

Subject has central nervous system involvement of multiple myeloma
Subject has received 10 mg/day prednisone equivalent within one week before starting Y150
Subject with primary or secondary plasma cell leukemia
Subject had a prior autologous stem cell transplant 12 weeks months prior to starting Y150, or had a prior autologous stem cell transplant history
Subject received a chimeric antigen receptor T (CAR T) cell product 6 months prior to starting Y150
Concurrent malignancy within 5 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer under active surveillance, prostate cancer that has undergone definitive treatment, ductal carcinoma in situ of the breast, or T1 urothelial carcinoma
Allergy to Abs drugs or human protein
Active infection(CTCAE Grade 2)
Subjects with severe respiratory disease, and to be unsuitable to participate in study by investigators judgment
Severe cardiovascular disease, including a history of CABG or PCI, myocardial infarction within 6 months of study entry, unstable angina ,NYHA class III or IV heart failure, uncontrolled hypertension or left ventricular ejection fraction <50%
QTc interval > 480 ms; Family or personal with a history of long or short QT syndrome; significant clinical history of ventricular arrhythmias, or currently receiving antiarrhythmic drugs or implanted defibrillator to treat ventricular arrhythmias
Patients with a history of active autoimmune diseases (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis etc.), except when the disease is in a stable state (without systemic immunosuppressant treatment, the symptoms are stable for more than 6 months)
Patients with severe hyperthyroidism or hypothyroidism
Patients with metabolic diseases such as uncontrolled diabetes, severe gastrointestinal bleeding, severe diarrhea (Grade 2 according to CTCAE), or severe gastrointestinal obstruction requiring intervention
Patients with a history of immunodeficiency, including HIV positive
HIV antibody, TP antibody and HCV antibody were positive, HBsAg positive and hepatitis B virus DNA test showed that patients with active hepatitis B (HBV-DNA 1000cps/ml)
Patients who have received inoculation of (attenuated) live virus vaccine within 4 weeks before the first administration
Pregnant, lactating women, or females or males who have fertility plan within 6 months during the study and after the end of the medication
Patients with a previous history of definite neurological or psychiatric disorders, and investigator believe that it affects patients' cognitive function or compliance, including unstable epilepsy, dementia, schizophrenia, etc
Any condition that the investigator believes may not be appropriate for participating the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note